Connect with Inverna Therapeutics at BIO-Europe Spring 2026 and LSX World Congress Europe 2026
Inverna Therapeutics is pleased to announce its participation in the…
Precision RNA splicing modulation
Inverna Therapeutics is dedicated to the development of an RNA therapeutics platform to modify RNA expression with unparalleled specificity. Leveraging sequence-specific activation of pseudo exons, we develop safer, more effective precision medicines for unmet medical needs.
Transforming RNA discovery into therapy
Inverna is pioneering RNA therapeutics with its proprietary pseudo-exon activation platform. By precisely modulating splicing, we control how genes are expressed, ultimately adjusting the expression of specific proteins to target disease at its source.
Our programs
We are advancing precision RNA splicing modulation therapies for neurodegenerative diseases, with lead programs focusing on Parkinson’s disease and Huntington’s disease.
Meet the team advancing RNA therapeutics
Behind Inverna is a team of scientists, innovators, and industry leaders dedicated to turning cutting-edge RNA research into real-world therapies.
Latest news
Inverna Therapeutics to Showcase Breakthrough Pseudo-Exon Activation Platform at RNA Leaders Europe Congress
Inverna Therapeutics is pleased to announce that Chief Executive Officer,…
Inverna Therapeutics will be presenting at BioCapital 2026
Inverna Therapeutics is pleased to announce that CEO Poul Sørensen…